Piper Jaffray assumed coverage on shares of Weibo Corp (ADR) (NYSE:WB). Piper Jaffray issued an overweight rating and a $25.00 price target on the stock. Weibo Corp (ADR) (NASDAQ:WB) net profit margin is -74.70% and weekly performance is -1.16%. On last trading day company shares ended up $19.52. Analysts mean target price for the company is $25.00. Weibo Corp (ADR) (NASDAQ:WB) distance from 50-day simple moving average (SMA50) is -0.66%.
Lattice Semiconductor Corporation (NASDAQ:LSCC) Amended 2013 Incentive Plan, the stockholders of Lattice Semiconductor Corporation approved the Lattice Semiconductor Corporation amended 2013 Incentive Plan (the “Amended 2013 Plan”) at the annual meeting of stockholders (the “Annual Meeting”). The Amended 2013 Plan was previously approved by the Board, upon recommendation by the Compensation Committee subject to stockholder approval at the Annual Meeting. Lattice Semiconductor (NASDAQ:LSCC) shares advanced 7.62% in last trading session and ended the day on $8.47. LSCC Gross Margin is 54.20% and its return on assets is 7.20%. Lattice Semiconductor (NASDAQ:LSCC) quarterly performance is 23.29%.
On May 8, BPZ Resources Inc (NYSE:BPZ) an independent oil and gas exploration and production company, today provided first quarter 2014 financial results and an operational update. First quarter ended March 31, 2014 operating income of $2.1 million, compared with an operating loss of $7.2 million for the same period last year, Net loss of $3.6 million or $0.03 loss per share, compared to $12.8 million or $0.11 loss per share for the same period last year. BPZ Resources Inc (NYSE:BPZ) shares moved up 12.74% in last trading session and was closed at $2.92, while trading in range of $2.69 – $2.93. BPZ Resources Inc (NYSE:BPZ) year to date (YTD) performance is 60.44%.
The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against Insys Therapeutics Inc (NASDAQ:INSY) resulting from allegations that the Company may have issued materially misleading business information to the investing public. media outlets reported that Dr. Gavin Awerbuch, a neurologist who was paid $6.9M from 2009, through Feb. 6, 2014, for his writing prescriptions of INSYS Therapeutics’ cancer pain drug Subsys, was arraigned in federal court in Detroit on charges of health care fraud. Awerbuch is responsible for approximately 20.3% of the Subsys prescribed to Medicare beneficiaries nationwide during this time. This adverse information has caused the price of INSYS stock to fall, damaging investors. Insys Therapeutics Inc (NASDAQ:INSY) ended the last trading day at $27.63. Company weekly volatility is calculated as 13.25% and price to cash ratio as 20.81. Insys Therapeutics Inc (NASDAQ:INSY) showed a negative weekly performance of -30.72%.